Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed it in a new indication of second line liver cancer – a use whe
The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali, who brings two decades of commercial experience and a bold vision for Ipsen’s globa
